SUPN Stock Recent News
SUPN LATEST HEADLINES
NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.